Publication: 117

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
      Google Scholar   
Citation:
Clin Genitourin Cancer vol 6 (2) 110-6
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
CA04326, CA04457, CA07968, CA11789, CA16450, CA31946, CA31983, CA32291, CA33601, CA35279, CA35421, CA41287, CA45389, CA45418, CA45808, CA47559, CA47642, CA60138, CA74811, CA77298, CA77406, CA77440, CA77597, CA77658  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-90004
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Aged, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Administration Schedule, Drug Resistance, Neoplasm, Estramustine, Humans, Male, Middle Aged, Prostate-Specific Antigen, Prostatic Neoplasms, Sulindac, Survival Analysis, Taxoids, Thromboembolism